- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
You are here
Rosette Lidereau, PhD
Department of Tumor Biology
Goal: To discover new preventive and treatment strategies for patients with metastatic breast cancer.
Impact: Dr. Lidereau has identified a protein called kindlin-1 that drives cancer cell invasion and metastasis. She and her team recently developed a molecule that blocks its function, which may prove to be a new therapeutic strategy to prevent tumors from spreading.
What’s next: The team plans to propose a new therapeutic approach for triple-negative breast cancers (TNBCs)—a type of breast cancer that is more likely to spread—by developing pharmacological inhibitors of kindlin-1.
Metastatic breast cancer, also called Stage IV, is the most advanced form of breast cancer. While there are ways to slow its growth, there is no cure for it, so interventions are urgently needed to prevent metastasis. Dr. Lidereau is studying the molecular mechanisms underlying breast cancer progression and has identified a potential target for drug development that would prevent tumors from spreading to other tissues.
Full Research Summary
Research area: Understanding the processes involved in metastasis, particularly how tumor cells can migrate, or move from one place to another—a characteristic normal breast cells do not have.
Impact: Dr. Lidreau’s studies of the early processes that lead to metastasis could inform the development of new strategies for preventing it. While there are ways to slow the growth of metastatic breast cancer (MBC), it is incurable. Preventing metastasis would save thousands of lives each year.
Current investigation: She and her team are studying the role of a gene called kindlin-1 in breast cancer lung metastasis, which they have discovered provides cancer cells with higher invasive capacities.
What she’s learned so far: Dr. Lidreau and has developed a molecule that blocks the function of kindlin-1, which inhibited cancer cell invasion in experimental models.
What’s next: The team will to continue to validate this new therapeutic approach. They also plan to further their genomic analyses of primary tumors and subsequent metastases to identify genes associated with breast cancer metastasis, the molecular processes driving organ-specific metastasis, and the potential drivers of resistance to treatments.
Dr. Rosette Lidereau received her PhD in oncology and immunology in 1987 from the Pasteur Institute (working with Chairman and Prof. Barret-Sinoussi) and completed a fellowship in the Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda (Prof. R. Callahan). In 1992, she was recruited by the INSERM (Institut National des Sciences et de la Recherche Médicale), where she served as a Research Director. From 2000, she headed the INSERM Unit U735, a laboratory dedicated to the molecular characterization of breast cancers at the Centre René Huguenin, Saint-Cloud, France.
Dr. Lidereau's scientific career has focused on the biology of breast cancer. Her research interests are the evaluation of oncogenes and the implication of tumor suppressor genes in breast tumorigenesis and their impact in the clinic as prognostic and predictive factors in breast cancer. Her work has been published in peer reviewed journals in which she has authored over 250 scientific articles. She has received several awards including the Henry et Mary-Jane Mitjavile prize from the Academy of Medicine (2005). In addition, she has been actively involved in numerous national and international organizations, including the international TRANSBIG research network and European Union Programmes (framework IV and VI).
Currently she pursues her research activities in the Genetics Laboratory in the Department of Tumor Biology at Institut Curie, Paris. Her investigations focus on the molecular determinants of breast cancer metastasis and their involvement in organ-specificity.